+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Acute Vasodilator Response in Pediatric Pulmonary Arterial Hypertension: Current Clinical Practice From the TOPP Registry



Acute Vasodilator Response in Pediatric Pulmonary Arterial Hypertension: Current Clinical Practice From the TOPP Registry



Journal of the American College of Cardiology 67(11): 1312-1323



In pulmonary arterial hypertension (PAH), acute vasodilator response testing (AVT) is considered important to identify adult patients with favorable prognosis using calcium-channel blocker (CCB) therapy. However, in pediatric PAH, criteria used to identify acute responders and CCB use are insufficiently studied. This study sought to describe current clinical practice of AVT and subsequent treatment decisions in pediatric PAH. From January 2008 to May 2013, 529 consecutive children with confirmed pulmonary hypertension were enrolled in an international registry. We analyzed those children with evaluable AVT. Of 382 children with evaluable AVT, 212 had idiopathic/familial PAH (IPAH/FPAH) and 105 had PAH associated with congenital heart disease (PAH-CHD). In 70% of the patients, AVT was performed using inhaled nitric oxide; other agents were used in the remaining patients. In IPAH/FPAH patients, 78 (37%) patients were acute responders according to their physician, 62 (30%) according to REVEAL (Registry-to-Evaluate-Early-And-Long-term PAH disease management)-pediatric criteria, and 32 (15%) according to Sitbon criteria. For PAH-CHD patients, the numbers of AVT responders were 38 (36%), 14 (13%), and 7 (7%) respectively. Correlation between AVT responder status as judged by the treating physician and by published response criteria was poor. Moreover, of the IPAH/FPAH patients judged by the treating physician as acute responders, only 23% were treated with CCB without additional PAH-targeted therapy. The Sitbon criteria selected patients with better prognosis who had excellent outcome when treated with CCB. The current practice of identifying responders to AVT and subsequent treatment with CCB therapy demonstrated large discrepancies with current international guidelines. Also, in pediatric IPAH, the Sitbon criteria are the criteria of choice to identify patients with excellent survival when treated with CCB therapy.

(PDF emailed within 0-6 h: $19.90)

Accession: 057131590

Download citation: RISBibTeXText

PMID: 26988953

DOI: 10.1016/j.jacc.2016.01.015


Related references

Meaningful and feasible composite clinical worsening definitions in paediatric pulmonary arterial hypertension: An analysis of the TOPP registry. International Journal of Cardiology 2019, 2019

Haemodynamic characterisation and heart catheterisation complications in children with pulmonary hypertension: Insights from the Global TOPP Registry (tracking outcomes and practice in paediatric pulmonary hypertension). International Journal of Cardiology 203: 325-330, 2016

Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: occurrence and prognostic value when comparing three response criteria. European Heart Journal 32(24): 3137-3146, 2012

Prognostic value of acute vasodilator response in pulmonary arterial hypertension: beyond the "classic" responders. Journal of Heart and Lung Transplantation 34(3): 312-318, 2015

Acute vasodilator test in pulmonary arterial hypertension: evaluation of two response criteria. Vascular Pharmacology 43(3): 143-147, 2005

Acute vasodilator response to vardenafil and clinical outcome in patients with pulmonary hypertension. European Journal of Clinical Pharmacology 71(10): 1165-1173, 2016

Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry. International Journal of Cardiology 172(3): 561-567, 2015

Acute pulmonary vasodilator testing with inhaled treprostinil in children with pulmonary arterial hypertension. Pediatric Cardiology 34(4): 1006-1012, 2013

Acute pulmonary vasodilator testing is a critical step in the management of patients with pulmonary arterial hypertension. Zhonghua Jie He He Hu Xi Za Zhi 31(5): 378-380, 2008

Acute vasodilator response during short-term infusion of prostacyclin in severe pulmonary hypertension Is there any clinical or haemodynamic predictor of responsiveness?. European Heart Journal 22(Abstract Supplement): 319, 2001

Red blood cell distribution width predicts responsiveness of acute pulmonary vasodilator testing in patients with idiopathic pulmonary arterial hypertension. Clinica Chimica Acta; International Journal of Clinical Chemistry 446: 272-276, 2016

Acute vasodilator testing in idiopathic pulmonary arterial hypertension: must we take NO for the answer?. European Respiratory Journal 33(6): 1247-1249, 2009

Right-heart function related to the results of acute pulmonary vasodilator testing in patients with pulmonary arterial hypertension caused by connective tissue disease. Journal of the American Society of Echocardiography 25(3): 274-279, 2012

What's in a side effect? The association between pulmonary vasodilator adverse drug events and clinical outcomes in patients with pulmonary arterial hypertension. International Journal of Cardiology 240: 386-391, 2017

Safe and effective exercise training for patients with pulmonary arterial hypertension: putting current evidence into clinical practice. Expert Review of Respiratory Medicine 12(11): 965-977, 2018